779 related articles for article (PubMed ID: 17583775)
1. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
[TBL] [Abstract][Full Text] [Related]
2. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
4. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.
Chen DY; Lan JL; Lin FJ; Hsieh TY
J Rheumatol; 2004 Nov; 31(11):2189-98. PubMed ID: 15517632
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokine profiles in patients with adult onset Still's disease.
Choi JH; Suh CH; Lee YM; Suh YJ; Lee SK; Kim SS; Nahm DH; Park HS
J Rheumatol; 2003 Nov; 30(11):2422-7. PubMed ID: 14677188
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and management of adult-onset Still's disease.
Efthimiou P; Georgy S
Semin Arthritis Rheum; 2006 Dec; 36(3):144-52. PubMed ID: 16949136
[TBL] [Abstract][Full Text] [Related]
8. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.
Giampietro C; Ridene M; Lequerre T; Costedoat Chalumeau N; Amoura Z; Sellam J; Sibilia J; Bourgeois P; Fautrel B;
Arthritis Care Res (Hoboken); 2013 May; 65(5):822-6. PubMed ID: 23225779
[TBL] [Abstract][Full Text] [Related]
9. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease.
Chen DY; Lan JL; Lin FJ; Hsieh TY; Wen MC
Ann Rheum Dis; 2004 Oct; 63(10):1300-6. PubMed ID: 15361391
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.
Nordström D; Knight A; Luukkainen R; van Vollenhoven R; Rantalaiho V; Kajalainen A; Brun JG; Proven A; Ljung L; Kautiainen H; Pettersson T
J Rheumatol; 2012 Oct; 39(10):2008-11. PubMed ID: 22859346
[TBL] [Abstract][Full Text] [Related]
11. A case of refractory adult-onset Still's disease treated with anakinra.
Lahiri M; Teng GG
Int J Rheum Dis; 2010 Aug; 13(3):e36-41. PubMed ID: 20704609
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of steroid refractory adult-onset Still's disease with anakinra.
Maier J; Birkenfeld G; Pfirstinger J; Schölmerich J; Fleck M; Brühl H
J Rheumatol; 2008 May; 35(5):939-41. PubMed ID: 18464320
[No Abstract] [Full Text] [Related]
13. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.
Naumann L; Feist E; Natusch A; Langen S; Krause A; Buttgereit F; Burmester GR
Ann Rheum Dis; 2010 Feb; 69(2):466-7. PubMed ID: 20107032
[No Abstract] [Full Text] [Related]
14. Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still's disease.
Jung KH; Kim JJ; Lee JS; Park W; Kim TH; Jun JB; Yoo DH
Scand J Rheumatol; 2014; 43(2):162-9. PubMed ID: 24134323
[TBL] [Abstract][Full Text] [Related]
15. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still's disease.
Chen DY; Lan JL; Lin FJ; Hsieh TY
Arthritis Rheum; 2005 Jun; 53(3):320-7. PubMed ID: 15934126
[TBL] [Abstract][Full Text] [Related]
16. Adult-onset Still's disease in a patient over 80 years old successfully treated with low-dose methotrexate therapy.
Kurasawa M; Kotani K; Kurasawa G; Shida K; Yamada S; Tago T
Age Ageing; 2007 Jan; 36(1):104-6. PubMed ID: 17158115
[TBL] [Abstract][Full Text] [Related]
17. Adult-onset Still's disease: clinical, serological and therapeutic considerations.
Iliou C; Papagoras C; Tsifetaki N; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2013; 31(1):47-52. PubMed ID: 23010097
[TBL] [Abstract][Full Text] [Related]
18. Steroid-resistant adult-onset Still's disease which showed a quick response to methotrexate.
Okamoto O; Oishi M; Fujiwara S
J Dermatol; 2008 Feb; 35(2):106-10. PubMed ID: 18271807
[TBL] [Abstract][Full Text] [Related]
19. Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease.
Chen DY; Hsieh TY; Hsieh CW; Lin FJ; Lan JL
Arthritis Rheum; 2007 Dec; 57(8):1530-8. PubMed ID: 18050226
[TBL] [Abstract][Full Text] [Related]
20. Refractory adult-onset still disease successfully treated with abatacept.
Ostrowski RA; Tehrani R; Kadanoff R
J Clin Rheumatol; 2011 Sep; 17(6):315-7. PubMed ID: 21869709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
